<DOC>
	<DOCNO>NCT01990248</DOCNO>
	<brief_summary>This multi-center , prospective , observational safety study evaluate safety effectiveness Zelboraf ( vemurafenib ) real world set . Data Zelboraf-treated patient BRAF-V600 mutation-positive unresectable metastatic melanoma collect 2 year .</brief_summary>
	<brief_title>An Observational Safety Study Zelboraf ( Vemurafenib ) -Treated Patients With BRAF-V600 Mutation-Positive Unresectable Metastatic Melanoma ( ZeSS )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adult patient age 18 year old Diagnosis BRAFV600 mutationpositive unresectable metastatic melanoma confirm validated test treat vemurafenib Vemurafenib treatment must initiate time enrollment one month prior enrollment Patient ( legally acceptable representative ) personally sign date informed consent document indicate informed pertinent aspect study , applicable Patient willing provide information least one alternate contact person study staff contact regard patient 's whereabouts , patient become lose followup course study Patient treat vemurafenib part clinical trial expand access program Patient participate study involve investigational study drug within one month prior initiate vemurafenib treatment Patient significant history disease medical condition ( except metastatic melanoma ) judgment investigator potential impact participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>